Literature summary for 3.2.1.166 extracted from

Barash, U.; Cohen-Kaplan, V.; Dowek, I.; Sanderson, R.D.; Ilan, N.; Vlodavsky, I.
Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis (2010), FEBS J., 277, 3890-3903.

Search for more literature for 3.2.1.166

Application

Application	Comment	Organism
medicine	increased heparanase levels are most often associated with reduced patient survival post operation, increased tumor metastasis and higher microvessel density	Homo sapiens

Molecular Weight [Da]

Molecular Weight [Da]	Molecular Weight Maximum [Da]	Comment	Organism
50000	-	x * 50000, SDS-PAGE	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
squamous cell carcinoma cell	-	Homo sapiens	-

Subunits

Subunits	Comment	Organism
?	x * 50000, SDS-PAGE	Homo sapiens

Expression

Organism	Comment	Expression
Homo sapiens	heparanase is upregulated in essentially all human carcinomas	up

General Information

General Information	Comment	Organism
physiological function	heparanase activity correlates with the metastatic potential of tumor-derived cells. Heparanase activity is implicated in neovascularization, inflammation and autoimmunity, involving the migration of vascular endothelial cells and activated cells of the immune system. Heparan sulfate cleavage by heparanase is required for structural remodeling of the extracellular matrix. Inactive heparanase facilitates adhesion and migration of primary endothelial cells and promotes phosphorylation of signaling molecules such as Akt and Src, facilitating gene transcription (i.e. vascular endothelial growth factor) and phosphorylation of selected Src substrates (i.e. endothelial growth factor receptor). Heparanase upregulates both the expression and shedding of syndecan-1 from the surface of myeloma cells	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)